Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.
Ontology highlight
ABSTRACT: One impediment to the use of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-targeted agents as antitumor drugs is the evolution of resistance, a common problem in cancer. On the contrary, many different kinds of drugs synergize with TRAIL in TRAIL-sensitive tumor cells, raising the question whether one can overcome resistance with the same drugs producing synergy. This is an important question, because recent clinical trials suggest that combination treatments with cytotoxic drugs and TRAIL receptor-targeted agents do not provide additional benefit compared with cytotoxic agents on their own. Such results might be expected if drug combinations that synergize in sensitive tumor cells but cannot overcome TRAIL resistance are used in patients whose tumors were not se
SUBMITTER: Menke C
PROVIDER: S-EPMC3250348 | biostudies-literature | 2011 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA